MariMed (MRMD) Stock Price, News & Analysis

Company Overview

MariMed, Inc. is a U.S.-based cannabis company that develops, operates, and manages state-licensed cannabis businesses. Its activities include cannabis cultivation, product manufacturing, wholesale distribution, and retail dispensary operations.

The company offers cannabis products such as flower, pre-rolls, concentrates, edibles, tinctures, and topical products. Its portfolio has included brands such as Betty’s Eddies, Nature’s Heritage, InHouse, and Kalm Fusion, which are distributed through MariMed-operated dispensaries and other licensed retail channels.

MariMed serves regulated cannabis markets in multiple states, including Massachusetts, Maryland, Delaware, and Ohio. The company was established in 2012 and has expanded through the development and acquisition of operating businesses in these markets. MariMed is led by Jon Levine, who serves as chief executive officer.

Key Stats

• Today's Range: $0.05 to $0.06
• 50-Day Range: $0.06 to $0.09
• 52-Week Range: $0.05 to $0.16
• Volume: 976,767 shs
• Average Volume: 590,661 shs
• Market Capitalization: $22.52 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Hold

MariMed Stock Analysis - MarketRank™

MariMed scored higher than 16% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.0 / 5
• Analyst Rating: Hold

Consensus Rating

MariMed has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, no buy ratings, 2 hold ratings, and no sell ratings.

Amount of Analyst Coverage

MariMed has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Book Value per Share Ratio

MariMed has a P/B Ratio of 0.43. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.00% of the float of MariMed has been sold short.

Short Interest Ratio / Days to Cover

MariMed has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in MariMed has recently decreased by 97.76%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

MariMed does not currently pay a dividend.

Dividend Growth

MariMed does not have a long track record of dividend growth.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for MariMed this week, compared to 1 article on an average week.

Company Ownership

• Score: 0.6 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, MariMed insiders have not sold or bought any company stock.

Percentage Held by Insiders

16.05% of the stock of MariMed is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

0.18% of the stock of MariMed is held by institutions.

Company Calendar

• Last Earnings: 8/12/2026
• Today: 10/21/2026
• AGM 2026: 10/28/2026
• Next Earnings (Estimated): 11/11/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:MRMD
• Previous Symbol: OTC:MRMD
• CIK: 1522767
• Web: marimedinc.com
• Phone: (617) 795-5140
• Fax: N/A
• Employees: 260
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($0.04)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$14.48 million
• Net Margins: -9.13%
• Pretax Margin: -6.21%
• Return on Equity: -10.71%
• Return on Assets: -2.58%

Debt

• Debt-to-Equity Ratio: 1.78
• Current Ratio: 0.92
• Quick Ratio: 0.34

Sales & Book Value

• Annual Sales: $159.83 million
• Price / Sales: 0.14
• Cash Flow: $0.02 per share
• Price / Cash Flow: 2.40
• Book Value: $0.13 per share
• Price / Book: 0.43

Miscellaneous

• Outstanding Shares: 402,950,000
• Free Float: 338,281,000
• Market Cap: $22.52 million
• Optionable: Not Optionable
• Beta: 1.39